ResultsIQ

ResultsIQ › Latest results › Hester Biosciences Limited

Hester Biosciences Limited Q3 FY26 earnings call summary

NSE: HESTERBIO · BSE: 524669

Earnings call of 30 Jan 2026, summarised by AI from the filing.

Hester Biosciences Q3 FY26 standalone revenue grew 12% and PAT up 140%, with Poultry Healthcare up 32%.

Key takeaways

  1. Q3 results Standalone revenue grew 12% and PAT up 140% year-on-year in Q3 FY26.
  2. Guidance Management expects EBITDA higher than ₹20 cr and assures margin improvement year-on-year.
  3. Change Fill/finish facility capitalized, doubling drug product capacity; depreciation impact from Q4 FY26.
  4. Driver Poultry Healthcare grew 32% in Q3 FY26 on deeper market penetration and demand for core vaccines.
  5. Risk Animal Health declined 38% in Q3 FY26 due to delays in government immunization programs.

Original filing on BSE

Hester Biosciences Limited Q1 FY27 results

As filed: Revenue ₹77.2 cr (−8% year on year), EBITDA ₹22.8 cr (−1% year on year), PAT ₹96.7 cr (−25% year on year), EBITDA margin 29.5% (+211 bps).

The Q1 FY27 score, against the company's own trend, is for premium members.

Earlier results and the share price after them

  • Q4 FY26: Revenue ₹100 cr (+22% year on year), EBITDA ₹34.3 cr (+81% year on year), PAT ₹16.6 cr (+300% year on year), EBITDA margin 34.3% (+1,000 bps). Score 87 of 100, Above trend. Revenue and profit before exceptional items growth were well above the company's own trend; EBITDA growth was above it. EBITDA margin rose 1000 bps year on year. Tax rate 37%. Revenue grew on the previous quarter, against its usual seasonal pattern. Share price after the results: +12.2% in 28 days (Nifty 500: −0.1%).
  • Q3 FY26: Revenue ₹77.4 cr (+23% year on year), EBITDA ₹17.8 cr (+300% year on year), PAT ₹9.3 cr (−15% year on year), EBITDA margin 23.0% (+1,000 bps). Score 71 of 100, Above trend. Revenue and EBITDA growth were well above the company's own trend; profit growth was below it. EBITDA margin rose 1000 bps year on year. Consolidated profit -15% but standalone +167%. Profit fell 34% from last quarter. Share price after the results: +6.5% in 28 days (Nifty 500: +0.1%).
  • Q2 FY26: Revenue ₹71.0 cr (−15% year on year), EBITDA ₹11.0 cr (−42% year on year), PAT ₹14.0 cr (+75% year on year), EBITDA margin 15.5% (−713 bps). Score 21 of 100, Below trend. Revenue and EBITDA growth were well below the company's own trend; profit growth was above it. EBITDA margin fell 713 bps year on year. Other income 67% of PBT. Consolidated profit +75% but standalone -22%. Revenue fell 15% from last quarter. Profit rose ₹6.0 cr on a year ago, more than the ₹4.0 cr it added the year before. Share price after the results: −2.1% in 30 days (Nifty 500: +0.2%).
  • Q1 FY26: Revenue ₹84.0 cr (+2% year on year), EBITDA ₹23.0 cr (+28% year on year), PAT ₹17.0 cr (+143% year on year), EBITDA margin 27.4% (+543 bps). Score 62 of 100, In line with trend. Revenue growth was in line with the company's own trend; EBITDA growth was above it; profit growth was well above it. EBITDA margin rose 543 bps year on year. Consolidated profit +143% but standalone +0%. Share price after the results: +3.9% in 28 days (Nifty 500: −2.0%).
  • Q4 FY25: Revenue ₹82.0 cr (+4% year on year), EBITDA ₹19.0 cr (+19% year on year), PAT ₹2.0 cr (−67% year on year), EBITDA margin 23.2% (+292 bps). Score 39 of 100, Below trend. Revenue growth was in line with the company's own trend; EBITDA growth was above it; profit growth was well below it. EBITDA margin rose 292 bps year on year. Tax rate 100%. Consolidated profit -67% but standalone +43%. Profit fell 82% from last quarter. Share price after the results: +10.0% in 28 days (Nifty 500: +6.1%).
  • Q3 FY25: Revenue ₹63.0 cr (−6% year on year), EBITDA ₹4.0 cr (−60% year on year), PAT ₹11.0 cr (+175% year on year), EBITDA margin 6.4% (−858 bps). Score 29 of 100, Below trend. Revenue growth was below the company's own trend; EBITDA growth was well below it; profit growth was well above it. EBITDA margin fell 858 bps year on year. Other income 67% of PBT. Consolidated profit +175% but standalone -33%. Revenue fell 25% from last quarter.
  • Q2 FY25: Revenue ₹84.0 cr (+20% year on year), EBITDA ₹19.0 cr (+46% year on year), PAT ₹8.0 cr (+100% year on year), EBITDA margin 22.6% (+405 bps). Score 86 of 100, Above trend. EBITDA margin rose 405 bps year on year. Not enough history for a trend yet: scored on growth alone.

Past price moves after results do not indicate future moves. Not a recommendation.

Hester Biosciences Limited earnings call, investor presentation and press release summaries

Figures from the company's filings with NSE and BSE. Not investment advice.